Literature DB >> 11166133

Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test.

T Yamamoto1, N Nozaki-Taguchi, Y Sakashita, T Inagaki.   

Abstract

N-acetyl-aspartyl-glutamate is a putative neurotransmitter and acts as a weak agonist at the N-methyl-D-aspartate receptor. N-acetyl-aspartyl-glutamate also acts as an agonist at the metabotropic glutamate receptor 3. N-acetyl-aspartyl-glutamate is hydrolyzed by N-acetylated-alpha-linked acidic dipeptidase to liberate N-acetyl-aspartate and glutamate. Recently, a specific inhibitor of N-acetylated-alpha-linked acidic dipeptidase, 2-(phosphonomethyl)pentanedioic acid, has been reported. In the present study, we examined the effect of i.t. administered 2-(phosphonomethyl)pentanedioic acid in the rat formalin test (a model of inflammatory pain) and the rat hot plate test. In the formalin test, drugs were administered 10min before (pre-treatment study) or 7min after (post-treatment study) the formalin injection. The paw formalin injection induces biphasic flinching (phase 1: 0-2min; phase 2: 10-60min) of the injected paw. In the pre-treatment study, i.t. administered 2-(phosphonomethyl)pentanedioic acid depressed both phases 1 and 2 flinching behavior in a dose-dependent manner but 2-(phosphonomethyl)pentanedioic acid had no effect on the flinching behavior in the post-treatment study. In the pre-treatment study, the potency of 2-(phosphonomethyl)pentanedioic acid in depressing the phase 2 response is greater than that in depressing the phase 1 response. Intrathecal injection of 2-(phosphonomethyl)pentanedioic acid had no effect in the hot plate test. We suggest that N-acetylated-alpha-linked acidic dipeptidase plays an important role in spinal nociceptive transmission and that inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect during the rat formalin test but not during the hot plate test.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166133     DOI: 10.1016/s0306-4522(00)00502-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

Review 1.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA).

Authors:  Rana Rais; Camilo Rojas; Krystyna Wozniak; Ying Wu; Ming Zhao; Takashi Tsukamoto; Michelle A Rudek; Barbara S Slusher
Journal:  J Pharm Biomed Anal       Date:  2013-08-30       Impact factor: 3.935

3.  Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.

Authors:  Anna Plechanovová; Youngjoo Byun; Glenda Alquicer; L'ubica Skultétyová; Petra Mlčochová; Adriana Němcová; Hyung-Joon Kim; Michal Navrátil; Ronnie Mease; Jacek Lubkowski; Martin Pomper; Jan Konvalinka; Lubomír Rulíšek; Cyril Bařinka
Journal:  J Med Chem       Date:  2011-10-11       Impact factor: 7.446

Review 4.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

5.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

6.  Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system.

Authors:  Valentina Alda Carozzi; Annalisa Canta; Norberto Oggioni; Cecilia Ceresa; Paola Marmiroli; Jan Konvalinka; Chiara Zoia; Mario Bossi; Carlo Ferrarese; Giovanni Tredici; Guido Cavaletti
Journal:  J Anat       Date:  2008-11       Impact factor: 2.610

7.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

8.  Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.

Authors:  Rana Rais; Randall Hoover; Krystyna Wozniak; Michelle A Rudek; Takashi Tsukamoto; Jesse Alt; Camilo Rojas; Barbara S Slusher
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

9.  NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation.

Authors:  Toshihiko Yamada; Daiying Zuo; Tatsuo Yamamoto; Rafal T Olszewski; Tomasz Bzdega; John R Moffett; Joseph H Neale
Journal:  Mol Pain       Date:  2012-09-12       Impact factor: 3.395

10.  N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors.

Authors:  Matteo Bernabucci; Serena Notartomaso; Cristina Zappulla; Francesco Fazio; Milena Cannella; Marta Motolese; Giuseppe Battaglia; Valeria Bruno; Roberto Gradini; Ferdinando Nicoletti
Journal:  Mol Pain       Date:  2012-10-23       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.